what is bpc-157 peptide | C62H98N16O22 | CID 9941957 BPC-157 – Research Peptide |

First, nausea was the most commonly reported GI adverse event across all dose groups but showed a non-monotonic dose-response pattern, peaking at the 12 mg dose (35.9%) rather than the highest dose

The overall safety and tolerability were similar between Reclast and active control groups with the exception of a higher incidence of post-dose symptoms in the Reclast group that occurred within 3 days after infusion

We believe responsible research is paramount

Restivo pays attention to detail and delivers great results! -J

This risk exists even in those using B12 for off-label purposes, as underlying undiagnosed B12 deficiency could be present